PT98944A - Processo de preparacao de anticorpos alterados e de composicoes farmaceuticas para a prevencao e tratamento de infeccoes - Google Patents

Processo de preparacao de anticorpos alterados e de composicoes farmaceuticas para a prevencao e tratamento de infeccoes

Info

Publication number
PT98944A
PT98944A PT98944A PT9894491A PT98944A PT 98944 A PT98944 A PT 98944A PT 98944 A PT98944 A PT 98944A PT 9894491 A PT9894491 A PT 9894491A PT 98944 A PT98944 A PT 98944A
Authority
PT
Portugal
Prior art keywords
infections
prevention
preparation
treatment
pharmaceutical compositions
Prior art date
Application number
PT98944A
Other languages
English (en)
Other versions
PT98944B (pt
Inventor
William J Harris
Philip R Tempest
Geraldine Taylor
Original Assignee
Scotgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotgen Ltd filed Critical Scotgen Ltd
Publication of PT98944A publication Critical patent/PT98944A/pt
Publication of PT98944B publication Critical patent/PT98944B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT98944A 1990-09-11 1991-09-11 Processo de preparacao de anticorpos alterados e de composicoes farmaceuticas para a prevencao e tratamento de infeccoes PT98944B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909019812A GB9019812D0 (en) 1990-09-11 1990-09-11 Novel antibodies for treatment and prevention of infection in animals and man

Publications (2)

Publication Number Publication Date
PT98944A true PT98944A (pt) 1992-08-31
PT98944B PT98944B (pt) 1999-02-26

Family

ID=10682003

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98944A PT98944B (pt) 1990-09-11 1991-09-11 Processo de preparacao de anticorpos alterados e de composicoes farmaceuticas para a prevencao e tratamento de infeccoes

Country Status (12)

Country Link
EP (1) EP0548190A1 (pt)
JP (1) JPH06501152A (pt)
KR (1) KR930702519A (pt)
AU (1) AU654827B2 (pt)
CA (1) CA2091335A1 (pt)
GB (1) GB9019812D0 (pt)
IE (1) IE913177A1 (pt)
MX (1) MX9101046A (pt)
NZ (1) NZ239728A (pt)
PT (1) PT98944B (pt)
WO (1) WO1992004381A1 (pt)
ZA (1) ZA917170B (pt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DK0539522T3 (da) * 1990-07-19 1999-08-30 Us Commerce Forbedret immunterapeutisk fremgangsmåde til hindring eller behandling af viral sygdom i luftvejene
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5646253A (en) * 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
DK0671927T3 (da) * 1992-09-16 2003-04-22 Us Gov Health & Human Serv Neutraliserende humane monoklonale antistoffer mod respiratorisk syncytialvirus
US6685942B1 (en) 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
WO1995004081A1 (en) * 1993-07-30 1995-02-09 Oravax, Inc. MONOCLONAL IgA ANTIBODY AGAINST RESPIRATORY SYNCYTIAL VIRUS
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
WO1995031546A1 (en) * 1994-04-28 1995-11-23 Scotgen Biopharmaceuticals, Inc. Recombinant human anti-varicella zoster virus antibodies
ATE194291T1 (de) 1995-09-18 2000-07-15 Intracel Corp Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
JP4503706B2 (ja) 1996-06-07 2010-07-14 ポニアード ファーマシューティカルズ，インコーポレイティド グリコシル化が改質されたヒト化抗体
DK0970206T3 (da) 1997-01-27 2008-10-13 Ludwig Inst Cancer Res Lage-1-tumorassocierede nukleinsyrer
EP2305235A1 (en) 1997-04-02 2011-04-06 The Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
HK1041009B (en) 1998-12-30 2009-05-08 Beth Israel Deaconess Medical Center, Inc. Characterization of the soc/crac calcium channel protein family
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
JP2003527826A (ja) 1999-06-30 2003-09-24 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 癌関連抗原およびその使用
PT1207905E (pt) 1999-09-03 2010-12-07 Brigham & Womens Hospital Métodos e composições para o tratamento de doença inflamatória utilizando agentes moduladores da caderina-11
KR20020047249A (ko) 1999-10-19 2002-06-21 에드워드 에이. 맥더모트, 주니어 Ｍａｇｅ-ａ12 항원성 펩티드 및 그의 용도
HK1049944A1 (zh) * 1999-12-23 2003-06-06 Icn Pharmaceuticals, Inc. L-核苷、l-核苷酸及其类似物的组合物和治疗方法
WO2001097843A2 (en) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CN101444621B (zh) 2003-02-11 2013-11-20 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
DK2384753T3 (en) 2003-08-29 2016-04-11 Brigham & Womens Hospital Hydantoin derivatives as inhibitors of cell necrosis
DE10341812A1 (de) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1795596A1 (en) 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
DE102005059242A1 (de) 2005-12-12 2007-06-14 Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten Molekulare Marker für eine Tumordiagnose und -therapie
CN101421411B (zh) 2006-04-13 2015-06-03 中外制药株式会社 牛磺酸转运蛋白基因
EP1911851A1 (en) 2006-10-12 2008-04-16 Ganymed Pharmaceuticals AG Compositions and methods for therapy and diagnosis of cancer and cancer metastasis
EP2118141B1 (en) 2007-02-23 2014-07-30 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that neutralize anthrax toxins
WO2008114673A1 (ja) 2007-03-15 2008-09-25 Chugai Seiyaku Kabushiki Kaisha ポリペプチドの製造方法
ES2591284T3 (es) 2007-08-07 2016-11-25 Chugai Seiyaku Kabushiki Kaisha Método para la producción de proteínas heterogéneas
WO2009051109A1 (ja) 2007-10-15 2009-04-23 Chugai Seiyaku Kabushiki Kaisha 異種タンパク質を高生産する細胞の作製方法
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
AU2008314973C1 (en) * 2007-10-24 2014-05-08 Chugai Seiyaku Kabushiki Kaisha A cell for use in production of heteroproteins and production method using the same
EP2108701A1 (en) 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
WO2010011697A1 (en) * 2008-07-21 2010-01-28 Immunomedics Inc. Structural variants of antibodies for improved therapeutic characteristics
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
ES2963717T3 (es) 2009-02-20 2024-04-01 Astellas Pharma Inc Métodos y composiciones para el diagnóstico y tratamiento del cáncer
EP2221375A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
US8741601B2 (en) 2009-04-22 2014-06-03 Chugai Seiyaku Kabushiki Kaisha Method for producing a cell capable of high-yield production of heteroproteins
EP2249159A1 (en) 2009-04-29 2010-11-10 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
RU2675997C2 (ru) 2009-11-11 2018-12-25 Ганимед Фармасьютикалз Аг Антитела, специфичные к клаудину 6 (cldn6)
EA201291065A1 (ru) 2010-04-16 2013-03-29 Байоджен Айдек Ма Инк. Антитела против vla-4
WO2011133894A2 (en) 2010-04-23 2011-10-27 Purdue Research Foundation Protein drug formulations and packages
AU2011248184B2 (en) 2010-05-04 2015-12-17 Board Of Regents, The University Of Texas System Detection and treatment of fibrosis
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
RS58087B1 (sr) 2011-05-13 2019-02-28 Ganymed Pharmaceuticals Gmbh Antitela za lečenje kancera koji eksprimira klaudin 6
US20140322723A1 (en) 2011-11-22 2014-10-30 President and Dellows of Harvard College Diabetes diagnosis through the detection of glycated proteins in urine
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CN106163560A (zh) 2014-01-24 2016-11-23 亨利·M·杰克逊军事医学促进基金会 针对亨德拉和尼帕病毒的f糖蛋白的抗体
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
US10899829B2 (en) 2016-02-23 2021-01-26 Indiana University Research And Technology Corporation Emapii neutralizing antibody limits influenza A virus (IAV)-induced lung injury
US11534496B2 (en) 2016-06-07 2022-12-27 The Brigham And Women's Hospital, Inc. Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
EP3625254B1 (en) 2017-07-31 2023-12-13 F. Hoffmann-La Roche AG Three-dimensional structure-based humanization method
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb

Also Published As

Publication number Publication date
IE913177A1 (en) 1992-03-11
GB9019812D0 (en) 1990-10-24
WO1992004381A1 (en) 1992-03-19
JPH06501152A (ja) 1994-02-10
NZ239728A (en) 1995-07-26
KR930702519A (ko) 1993-09-09
AU654827B2 (en) 1994-11-24
MX9101046A (es) 1992-05-04
ZA917170B (en) 1992-07-29
EP0548190A1 (en) 1993-06-30
PT98944B (pt) 1999-02-26
CA2091335A1 (en) 1992-03-12
AU8505891A (en) 1992-03-30

Similar Documents

Publication Publication Date Title
BR1100850A (pt) Composto, processo para a preparação de um composto, e, composição farmacêutica
PT87259A (pt) Processo para a preparacao de composicoes farmaceuticas contendo 17-cetoesteroides apropriadas para o tratamento e a profilaxia de infeccoes retrovirais
BR9609701A (pt) Composição farmacéutica composto e processo para a preparação de compostos
BR9404114A (pt) Composição farmacêutica e seu processo de preparação
BR9611986A (pt) Compostos processo para a preparação dos mesmos composição farmcéutica e utilização dos compostos
BR9609780A (pt) Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto
BR9600821A (pt) Composto formulação farmacêutica e processo para a preparação de um composto
BR9506473A (pt) Composto processo para a preparação de compostos utilização de um composto composição farmacêutica e processo para o tratamento de infecções anti-fúngicas
FI921875A7 (fi) Menetelmä lääkeaineina käyttökelpoisten bentsisotiatsoli- ja bentsisoksatsoli-3-karboksiamidien valmistamiseksi
BR9204361A (pt) Composto e processo para sua preparacao formulacao farmaceutica e intermediario
BR9604894A (pt) Derivado de acetamida processo para a preparação do mesmo e uma composição farmacêutica contendo o mesmo
BR9407869A (pt) Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose
BR9408148A (pt) Processo para tratamento de arritmia composto e formulação farmacêutica
BR9612135A (pt) Taxóides processo para sua preparação e composiç o farmacêutica
BR9612204A (pt) Composto uso do composto composição farmacêutica e processo para preparação do composto e para o tratamento de dor
BR9103036A (pt) Composto,formulacao farmaceutica e processo para a preparacao do composto
MX9101046A (es) Anticuerpos novedosos para el tratamiento y prevencion de infeccion de animales y el hombre
BR9502471A (pt) Composto de guanidina processo para preparar um composto de guanidina composição farmaceutica uso de um composto de guanidina método para o tratamento profilático ou terapêutico de doenças e processo para preparar uma composição farmacêutica
BR9101121A (pt) Composto,processo para sua preparacao,suas aplicacoes,e preparado farmaceutico
BR9206950A (pt) Composição farmacêutica e processo para sua preparação
BR9607346A (pt) Composto utilizaç o de um composto composiç o farmacéutica e processo para o tratamento de um mamifero e para e preparaç o de compostos
BR9301180A (pt) Processo para a preparacao de isocianatos e emprego
BR9506106A (pt) Composto processo para sua preparação medicamento e composição farmacêutica
PT97749A (pt) Processo para a preparacao de composicoes farmaceuticas contendo dsarn apropriadas para o diagnostico e o tratamento de hepatite viral
FI960254A7 (fi) Menetelmä N-(4-hydroksifenyyli)-retiiniamidin valmistamiseksi

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19920407

FG3A Patent granted, date of granting

Effective date: 19981109

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20000531